Bank of England widely expected to hold interest rates despite big US Fed cut
Zimbabwe's new currency faces headwinds five months on
Pakistani blasphemy suspect's family forgives police officer accused of killing him
Jimmy Carter receives Holbrooke award from Dayton Literary Peace Prize Foundation
Euro zone current surplus shrinks
Cuban dissident leader wins Norwegian human rights award
The Thai zoo home to baby hippo and internet sensation Moo Deng is patenting the pygmy
A flying bat and a baserunning mistake cost Mariners chance to make up ground in playoff race
(Reuters) - Pfizer Inc on Friday cut forecast for 2023 revenue to between $58 billion and $61 billion, from $67 billion to $70 billion previously.
Shares of the company were down about 7% in extended trading.
The company also reduced its outlook for Paxlovid revenues by about $7 billion. It had previously expected Paxlovid revenues of about $8 billion.
Pfizer added the U.S. government will be returning an estimated 7.9 million doses of Paxlovid at the end of this year. (This story has been corrected to say that the revenue outlook for Paxlovid was reduced by $7 billion, not to $7 billion, in paragraph 3)
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
